UNSPSC 51381800: Nonsteroidal anti inflammatory acetates

Nonsteroidal anti inflammatory drugs made from derivatives of acetic acid, hence the name ACETATES; these may include acid forms, salts, esters, and amides that contain the carboxymethane structure.

UNSPSC 51381800 Nonsteroidal anti-inflammatory acetates is a Class code that, based on recent state and local opportunities, encompasses pharmaceutical procurement across multiple product categories including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products supplied to public health agencies and state employee benefit programs. The actual buying activity under this code spans community health departments, state health commissions, and multistate cooperative purchasing alliances sourcing pharmaceutical products for public health initiatives, emergency response programs, and employee health benefits. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing vehicles serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes participating Oregon facilities). Vendors must meet manufacturing compliance requirements including current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certification, maintain authorized wholesaler relationships, and provide detailed product documentation with National Drug Codes and pricing in multiple formats.

Recent activity shows geographic spread across Florida, Texas, and Minnesota with multistate reach through cooperative purchasing. The Seminole County IFB (IFB60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, using a fixed-fee competitive bidding process. Texas HHS issued an RFI (HHS0017013, April 3, 2026) to gather vendor capability information for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendors with direct-contracting experience in self-insured health plans and capacity for value-based agreements. MMCAP's RFP (S1070000015802, response deadline March 26, 2026) established multiple-award contracts for generic pharmaceuticals and OTC products to be effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee agreement. Vendors must carry commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, with contract terms typically two years and optional renewals.